Is ephedrine caffeine treatment contraindicated in hypertension?

International Journal of Obesity

Volumn 21, Issue 8, 1997, Pages 666-673

  Ingerslev, J ^a   Svendsen, T L ^b   Mork A ^c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Medical Department   (Denmark)

^c Nycomed Denmark   (Denmark)

Author keywords

adrenergic receptor blocking agents (betablockers); Anorexigenic agents; Hypertension; Obesity

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; EPHEDRINE; LETIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; SYSTOLIC BLOOD PRESSURE; TREMOR; WEIGHT REDUCTION;

EID: 0030842906     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800457     Document Type: Article

References (16)

1. 1988 Joint National Committee. The report of joint national committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1988; 148: 1023-1038.
2. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes 1992; 16: 269-277.
3. Goodman Gilman A, Rall TW, Nies AS, Taylor (eds). Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 8th edn. Pergamon Press, Inc, New York: 1990, pp 213-214.
4. Tashkin DP, Meth R, Simmons DH, Lee YE. Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine. Chest 1975; 68: 155-161.
5. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic, metabolic, and cardiovascular effects of a sympathomimetic agent, ephedrine. Curr Ther Res 1990; 48: 1087-1100.
6. World Health Organization. 1986 guidelines for the treatment of mild hypertension: Memorandum from a WHO/ISH meeting. Bulletin of the WHO 1986; 64: 31-35.
7. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1-6.
8. Mansson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter BS, Hankinsson SE et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
9. Drenick EJ, Bale GS, Seltzer F et al. Excessive mortality and causes of death in morbidly obese men. JAMA 1980; 243: 443-445.
10. Kampmann JP, Gram LF, Nielsen-Kudsk F, Schou JS.Basal og klinisk farmakologi. 1. Udgave. FADL's forlag, Copenhagen: 1994, p 71.
11. Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr 1988; 42: 83-94.
12. Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds). (1990): Goodman & Gilman's, The Pharmacological Basis of Therapeutics. 8th edn. Pergamon Press, Inc, New York: 1990, pp 620-622.
13. Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance of the humoral and hemodynamic effects of caffeine in man. Clin Invest 1981; 67: 1111-1117.
14. Astrup A, Toubro S, Cannon, Hein P, Breum L, Madsen J. Caffeine: A double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990; 51: 759-767.
15. Just SL, Bruun NE. Hypertension efter Helsingør-piller. Ugeskr Lœger 1988; 150: 27.
16. Breum L, Pedersen JK, Ahlstrøm F, Frimodt-Møller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multicentre trial in general practice. Int J Obes 1994; 18: 99-103.